Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
AcTFirst Trial Design for Actinium-225 PSMA-617 in Taxane-Naive mCRPC - Oliver Sartor
1+ day, 18+ hour ago (744+ words) Oliver Sartor discusses AcTFirst, a randomized trial evaluating PSMA-617 actinium-225 in taxane-naive metastatic castration-resistant prostate cancer. Patients progressed on ADT and an ARPI, and the flexible control arm permits docetaxel or a second-line ARPI, with lutetium PSMA also allowed. Radiographic…...
Azafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidoses
2+ day, 5+ hour ago (323+ words) The study enrolled at least 75 patients across 25 clinical sites in 13 countries. A part of the company’s NAVIGATE programme, the trial aims to assess the effects of nizubaglustat, an orally administered small molecule, on neurological manifestations and disease progression in these…...
Laminar Pharma Completes LAM561 Phase 2b/3 Trial in Glioblastoma
2+ day, 8+ hour ago (468+ words) The Clinical Trial Vanguard Laminar Pharma Completes LAM561 Phase 2b/3 Trial in Glioblastoma One interim signal has carried Laminar Pharma’s LAM561 program far enough to reach a full enrollment close, and the statistical design now does the waiting. The Spanish biotech announced last…...
SCI-110’s Phase IIb in Tourette Syndrome: What Hannover Tells Us About Cannabinoid Trial Design in CNS
1+ week, 3+ day ago (210+ words) On July 15, 2026, a Phase IIb site went live at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based treatment candidate targeting Tourette Syndrome in adults. The sponsor is NeuroThera Labs, a subsidiary of SciSparc Ltd. The activation is quiet…...
Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
1+ week, 5+ day ago (283+ words) More than ten countries and more than twenty sites are now participating in the Company's global pivotal trial for Huntington's disease, with over 175 patients enrolled. SKY-0515's Phase 1/2 enrollment is complete and it has been generally well tolerated with twelve…...
Eugen Leo: The Long-term Follow-up of the First-in-human Phase 1/2a Trial of Visugromab is Out - OncoDaily
2+ week, 2+ hour ago (211+ words) Eugen Leo, Founder and CEO of LEOConsulting, shared a post on LinkedIn: “The long-term follow-up of the first-in-human Phase 1/2a trial of visugromab (the GDFATHER01 trial) is out! The brand-new publication in the Journal of Hematology and Oncology by Ignacio Melero et…...
Hanmi Pharm's phase 2 melanoma trial advances as planned
2+ week, 2+ day ago (244+ words) Hanmi Pharmaceutical said Friday that its domestic phase 2 clinical trial of belvarafenib, an oral targeted anticancer drug for the treatment of melanoma, is progressing as planned. Belvarafenib is the first novel compound discovered by Hanmi Pharmaceutical. The oral targeted therapy…...
Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema)
2+ week, 3+ day ago (1021+ words) BioSpace Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema) TORONTO, July 8, 2026 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) has officially received a long-awaited positive recommendation (reimbursement with conditions) from Canada's Drug Agency…...
Seres Therapeutics reports 80% immunosuppressive-free response for SER-155 in irEC IST
2+ week, 4+ day ago (148+ words) TradingView Seres Therapeutics reports 80% immunosuppressive-free response for SER-155 in irEC IST Seres Therapeutics reported 80% of SER-155 recipients achieved an immunosuppressive-free clinical response at Day 15 in an IST for immune checkpoint inhibitor-related enterocolitis. - 12 of 15 patients (80%) met primary endpoint: ≥1-grade diarrhea improvement…...
Altesa BioSciences Announces Upcoming Oral Presentation Featuring Novel Vapendavir Data at European Respiratory Society International Congress 2026
2+ week, 5+ day ago (148+ words) Jul 07, 2026, 07:00 ET Acute exacerbations of COPD (AECOPD) are the primary driver of morbidity and mortality in COPD patients and are associated with accelerated lung function decline and diminished quality of life. Rhinovirus infection is responsible for approximately half of all…...